Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)

被引：0

作者：

Yokouchi, H. ^{[1
]}

Mizugaki, H. ^{[2
]}

Ikezawa, Y. ^{[3
]}

Morita, R. ^{[4
]}

Tateishi, K. ^{[5
]}

Yokoo, K. ^{[6
]}

Sumi, T. ^{[7
]}

Kikuchi, H. ^{[8
]}

Nakamura, A. ^{[9
]}

Kobayashi, M. ^{[10
]}

Aso, M. ^{[11
]}

Tsukita, Y. ^{[12
]}

Yoshiike, F. ^{[13
]}

Furuta, M. ^{[14
]}

Tanaka, H. ^{[15
]}

Sekikawa, M. ^{[16
]}

Hachiya, T. ^{[17
]}

Nakamura, K. ^{[18
]}

Kitamura, Y. ^{[19
]}

机构：

[1] Hokkaido Canc Ctr, Dept Resp Med, Fukushima, Japan

[2] Japanese Fdn Canc Res, Canc Immunotherapy Dev, Adv Med Dev Ctr, Canc Inst Hosp, Koto Ku, Tokyo, Japan

[3] Oji Gen Hosp, Dept Resp Med, Tomakomai, Japan

[4] Akita Kousei Med Ctr, Thorac Oncol, Akita, Nishibukuro, Japan

[5] Shinshu Univ, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano, Japan

[6] Teine Keijinkai Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan

[7] Hakodate Goryoukaku Hosp, Dept Resp Med, Hakodate, Hokkaido, Japan

[8] JA Hokkaido Kouseiren Obihiro Kosei Gen Hosp, Dept Resp Med, Obihiro, Hokkaido, Japan

[9] Sendai Kousei Hosp, Dept Resp Med, Sendai, Miyagi, Japan

[10] Miyagi Canc Ctr, Resp Med, Natori, Miyagi, Japan

[11] Yamagata Prefectural Cent Hosp, Pulm Med, Yamagata, Japan

[12] Tohoku Univ, Dept Resp Med, Sendai, Miyagi, Japan

[13] Nagano Municipal Hosp, Dept Resp Med, Nagano, Japan

[14] Hokkaido Univ Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan

[15] Hirosaki Univ, Dept Resp Med, Hirosaki, Aomori, Japan

[16] Steel Mem Muroran Hosp, Dept Resp Med, Muroran, Hokkaido, Japan

[17] Suwa Red Cross Hosp, Dept Resp Med, Suwa, Japan

[18] Natl Hosp Org Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Hokkaido, Japan

[19] Kushiro City Gen Hosp, Dept Resp Med, Kushiro, Japan

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.10.373

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

335P

引用

页码：S1574 / S1574

页数：1

共 50 条

[21] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
Wang, Q.
Ma, C.
Wang, T.
Chen, G.
Wang, H.
Mei, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1063 - S1063
[22] Real-world data on efficacy and safety of pembrolizumab in the first-line treatment of metastatic lung cancer in patients with PD-L1 expression >0% - a single center experience
Cvijic, T.
Canjko, I.
Tomas, I.
Kralik, K.
Peric, L.
Kotromanovic, D.
Dupan, Z. Krivdic
Peic, A. Kovac
Mimica, S.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (19) : 9213 - 9225
[23] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
Shang, X. Q.
Wang, T.
Chen, G.
Ma, C.
Wang, H.
Jia, X.
Mei, J.
ANNALS OF ONCOLOGY, 2022, 33 : S1550 - S1550
[24] Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
Kenji Morimoto
Tadaaki Yamada
Hayato Kawachi
Motohiro Tamiya
Yoshiki Negi
Yasuhiro Goto
Akira Nakao
Shinsuke Shiotsu
Keiko Tanimura
Takayuki Takeda
Asuka Okada
Taishi Harada
Koji Date
Yusuke Chihara
Isao Hasegawa
Nobuyo Tamiya
Naoya Nishioka
Yuki Katayama
Masahiro Iwasaku
Shinsaku Tokuda
Takashi Kijima
Koichi Takayama
Targeted Oncology, 2023, 18 : 915 - 925
[25] Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
Morimoto, Kenji
Yamada, Tadaaki
Kawachi, Hayato
Tamiya, Motohiro
Negi, Yoshiki
Goto, Yasuhiro
Nakao, Akira
Shiotsu, Shinsuke
Tanimura, Keiko
Takeda, Takayuki
Okada, Asuka
Harada, Taishi
Date, Koji
Chihara, Yusuke
Hasegawa, Isao
Tamiya, Nobuyo
Nishioka, Naoya
Katayama, Yuki
Iwasaku, Masahiro
Tokuda, Shinsaku
Kijima, Takashi
Takayama, Koichi
TARGETED ONCOLOGY, 2023, 18 (06) : 915 - 925
[26] Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer
Shah, Mohsin
Marmarelis, Melina E.
Mamtani, Ronac
Hennessy, Sean
CLINICAL LUNG CANCER, 2022, 23 (08) : 731 - 736
[27] Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)
Velcheti, Vamsidhar
Chandwani, Sheenu
Chen, Xin
Pietanza, M. Catherine
Burke, Thomas
CANCER RESEARCH, 2019, 79 (13)
[28] First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience
Benetti, B.
Ferro, A.
Girardi, F.
Calvetti, L.
Pavan, A.
Mulargiu, C.
Simionato, F.
Pretelli, G.
Lorenzi, M.
Resi, M. V.
Marinato, G.
Dal Maso, A.
Frega, S.
Pasello, G.
Aprile, G.
Morandi, P.
Guarneri, V.
Bonanno, L.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S341 - S341
[29] Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with ≥50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study
Perea, J.
Gomez, E.
Escriva, C.
Pellicer, A. V.
Rodriguez, P. Llor
Iranzo, J.
Vidal, O. J. Juan
Sanchez, J. Garcia
Montagud, G. Suay
Mico, A. Ferrero
Diaz, J. Linares
Sepulveda, N. Gomez
Hernandez, E. Soria
Gallego, J. Esteve
Carrasco, C.
Gaudens, P. Capdevila
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S72 - S73
[30] Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.
Aguilar, Elizabeth Jimenez
Ricciuti, Biagio
Gainor, Justin F.
Nishino, Mizuki
Adeni, Anika E.
Subegdjo, Safiya
Khosrowjerdi, Sara
Peterson, Rachel
Digumarthy, Subba
Liu, Corinne
Sauter, Jennifer L.
Rizvi, Hira
Arbour, Kathryn Cecilia
Carter, Brett W.
Heymach, John
Altan, Mehmet
Hellmann, Matthew David
Awad, Mark M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →